Texting patients could boost psoriasis drug success
NCT ID NCT05570955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether weekly text reminders help people with psoriasis take their deucravacitinib medication as prescribed. Forty patients will be split into two groups: one gets reminders, the other does not. Researchers will interview participants to understand what helps or hinders sticking to the treatment, and compare skin improvement between those who take the drug regularly and those who don't.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deucravacitinib
What this could lead to
If successful, this could show that simple text reminders help people take their psoriasis medication more consistently, leading to better real-world results.
What could go wrong
This is a small, early-stage study with only 40 participants, so findings may not apply to everyone. It focuses on adherence behavior, not on whether the drug itself works better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, 27157, United States